Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Daneshmand S, Kamat AM, Shore ND, Meeks JJ, Galsky MD, Jacob JM, van der Heijden MS, Williams SB, Powles T, Chang SS, Catto JWF, Psutka SP, Guerrero-Ramos F, Xylinas E, Miyake M, Simone G, Daniel K, Sweiti H, Cutie C, Necchi A.
Daneshmand S, et al. Among authors: chang ss.
Urol Oncol. 2025 Jan 15:S1078-1439(24)01044-5. doi: 10.1016/j.urolonc.2024.12.264. Online ahead of print.
Urol Oncol. 2025.
PMID: 39818460
Review.